Irbesartan + Hidroclorotiazida Bluepharma (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the angiotensin II type 1 receptors, preventing vasoconstriction and the release of aldosterone. This leads to relaxation of blood vessels and reduced fluid retention, contributing to lower blood pressure when used together with the diuretic component.

The appropriate dose is determined by the prescribing healthcare professional based on the patient’s medical condition, response to therapy, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Irbesartan + Hidroclorotiazida Bluepharma is classified as Pregnancy Category D, indicating potential risk to the fetus, especially in the second and third trimesters. It is generally not recommended for use during pregnancy, and breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

The Irbesartan/Hydrochlorothiazide combination offers dual‑action blood pressure control by targeting both the renin‑angiotensin system and fluid volume. Compared with monotherapy agents, it can achieve greater reductions in blood pressure with a single tablet, potentially improving adherence while maintaining a safety profile similar to its individual components.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and ensure the container is tightly closed to maintain product stability.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water and do not crush or chew it unless specifically instructed.

Serious risks include severe dehydration, significant electrolyte disturbances such as hypokalemia or hyponatremia, acute kidney injury, marked hypotension, and rare cases of angioedema. Patients should be monitored regularly for these conditions, especially during therapy initiation or dose changes.

The combination is contraindicated in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in pregnant women beyond the first trimester, individuals with severe renal impairment, and those taking potassium‑sparing diuretics without close medical supervision.